Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance last spring.

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Ta ...

Harness Therapeutics, a Cambridge biotech unlocking previously undruggable targets to transform the treatment of ...

Last June, Ascentage granted Takeda Pharmaceuticals International an exclusive option to license olverembatinib for development and commercialization outside of greater China and Russia.

Protein degradation–focused Neomorph nabs its third Big Pharma deal of around $1.5 billion in less than a year.

A US lawsuit filed on behalf of LinkedIn Premium users accuses the social media platform of sharing their private messages with other companies to train artificial intelligence (AI) models.

Immune checkpoint blockers (ICBs) have revolutionized the treatment of non–small cell lung cancer (NSCLC). Currently, one-dose-fits-all maximalist regimens have been considered the standard of care, ...

See Correction/Clarification at the end of this article. After layoffs in 2024, Takeda is gearing up for a big 2025 that includes preparations to launch three new medicines, hiring, and finishing ...